LearnGlossaryMarketStocksSuperinvestorsSign in

SYRE

Spyre Therapeutics, Inc.

Healthcare · $7.5B market cap

Verdict

We can't put a fair value on SYRE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-24.7% a year✗
Sales growth-13.9% a year✗
Free cash flow growth—?
Return on invested capital-48.3%✗

Follow SYRE

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases, 14 sales worth $6.1M and 3 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Burrows Scott L

Chief Financial Officer · 2026-09-02

Sold

$1.6M

King-Jones Heidy

See Remarks · 2026-09-02

Sold

$36K

Turtle Cameron

Chief Executive Officer · 2026-09-01

Sold

$36K

Turtle Cameron

Chief Executive Officer · 2026-09-01

Sold

$326K

Turtle Cameron

Chief Executive Officer · 2026-09-01

Sold

$732K

Show all 14 sales

Turtle Cameron

Chief Executive Officer · 2026-09-01

Sold

$216K

Burrows Scott L

Chief Financial Officer · 2026-09-01

Sold

$18K

Burrows Scott L

Chief Financial Officer · 2026-09-01

Sold

$177K

Burrows Scott L

Chief Financial Officer · 2026-09-01

Sold

$382K

Burrows Scott L

Chief Financial Officer · 2026-09-01

Sold

$78K

King-Jones Heidy

See Remarks · 2026-09-01

Sold

$36K

King-Jones Heidy

See Remarks · 2026-09-01

Sold

$547K

King-Jones Heidy

See Remarks · 2026-09-01

Sold

$1.4M

King-Jones Heidy

See Remarks · 2026-09-01

Sold

$419K

Other filings

King-Jones Heidy

See Remarks · 2026-09-02

Option exercise

$6K

Burrows Scott L

Chief Financial Officer · 2026-09-01

Option exercise

$109K

King-Jones Heidy

See Remarks · 2026-09-01

Option exercise

$406K

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works